RUNX2 and bone cancer: Together, these findings point to a role for RUNX2 in BCSCs, in the diagnosis of bone cancer, and in treatment resistance, all of which provide credence to the hypothesis that RUNX2 might serve as a therapeutic target for anticancer drugs in the future.